DOCSLIB.ORG

2011 Soft - Tiaft

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2011 Soft - Tiaft 2011 SOFT - TIAFT JOINT MEETING OF THE SOCIETY OF FORENSIC TOXICOLOGISTS & THE INTERNATIONAL ASSOCIATION OF FORENSIC TOXICOLOGISTS PROGRAM & ABSTRACTS 25 – 30 SEPTEMBER 2011 MARRIOTT MARQUIS SAN FRANCISCO HOTEL SAN FRANCISCO, CALIFORNIA, USA 25 September 2011 Dear Colleagues and Friends, I am honored and privileged to welcome you to San Francisco, California for the 2011 Joint SOFT-TIAFT International Conference & Exposition on Forensic and Analytical Toxicology. Our gathering encompasses the 41st Annual Meeting of the Society of Forensic Toxicologists and the 49th Annual Meeting of The International Association of Forensic Toxicologists. 2011 is UNESCO’s International Year of Chemistry and you could not have chosen a better way to celebrate than by participating in the 2011 Joint SOFT-TIAFT Meeting. This year we have broken every record in exhibitor participation, which ensures that you will see firsthand the best products, services and equipment that our extraordinary exhibitors have to offer. And with more than 500 submitted abstracts from dozens of countries, the final scientific program is guaranteed to both educate and inspire! San Francisco is a colorful and breathtaking metropolis that has re-established itself as the economic and cultural hub of the American West following the 7.8 magnitude earthquake of 1906 that devastated the entire region and killed thousands. In 2011, 105 years after the earthquake, the City remains a beacon for visitors from around the world. From the famous icons of Golden Gate Bridge and Alcatraz Island to the Cable Cars and the exquisite art galleries at SFMOMA, the City takes pride in its unrivaled attractions, renowned museums, and unique neighborhoods that are treasures of their own. While in town, please take time to explore this wonderful ‘left coast’ urban destination and discover the incredible variety of sites, shops, and restaurants that define the City's great ethnic and cultural diversity. As host of this year’s conference – 15 years after attending my first TIAFT meeting in 1996 in Thessaloniki, Macedonia, Greece and 13 years after my first Joint SOFT-TIAFT meeting in 1998 in Albuquerque, New Mexico – I am reminded of the global success our field enjoys. Also reinforced is how supportive more seasoned forensic toxicologists are towards younger members, enabling us to aim high and reap the benefits of belonging to a large international family of colleagues and friends ready to assist, promote and help us succeed! As Chairman of the 2011 Joint SOFT-TIAFT Meeting, I have had the privilege of working with an extraordinary Organizing Committee, a distinguished International Advisory Board and a myriad of volunteers from around the world. Their collective and tireless support and assistance during the last four years today permits us to provide you with a cutting- edge scientific program that represents the worldwide state-of-the-art in forensic and analytical toxicology. We are also proud of the rejuvenating social calendar that we hope all will find entertaining against the backdrop of this amazingly diverse City. Welcome to San Francisco! Nikolas P. Lemos, PhD, FRSC, D-ABFT Chairman, 2011 Joint SOFT-TIAFT International Conference & Exposition on Forensic and Analytical Toxicology Chief Forensic Toxicologist & Clinical Professor Director, Forensic Laboratory Division Department of Laboratory Medicine Office of the Chief Medical Examiner School of Medicine City and County of San Francisco The University of California, San Francisco 2011 SOFT -TIAFT Organizing Committee Nikolas P. Lemos Committee Chairman & Host Ann Marie Gordon CoCoCo-Co ---HostHost Daniel S. Isenschmid Treasurer Vina R. Spiehler IntIntInternationalInt ernational Delegate Liaison Marilyn A. Huestis Scientific Program Laureen Marinetti Workshops Dimitri Gerostamoulos Workshops Jeri Ropero ---Miller Sponsors & Exhibitors Peter R. Stout Sponsors & Exhibitors SOFT TIAFT BOARD OF DIRECTORS EXECUTIVE COMMITTEE Sarah Kerrigan, Ph.D. Olaf H. Drummer, Ph.D. SOFT President TIAFT President Marc A. LeBeau, Ph.D. Alain G. Verstraete, M.D. SOFT Vice President TIAFT President-Elect Dan T. Anderson, M.S. Pascal Kintz, Ph.D. SOFT Secretary TIAFT Past President Peter R. Stout, Ph.D. Hee-Sun Chung, Ph.D. SOFT Treasurer TIAFT Secretary Adam Negrusz, Ph.D Daniel S. Isenschmid, Ph.D. Director TIAFT Treasurer Fiona J. Couper, Ph.D. Marc A. LeBeau, Ph.D. Director Board Member Jeri D. Ropero-Miller, Ph.D. Hans H. Maurer, Ph.D. Director Board Member Jennifer F. Limoges, M.S. Anya Pierce, M.B.A. Director Board Member Bruce A. Goldberger, Ph.D. Director The 2011 SOFTSOFT----TIAFTTIAFT Organizing Committee wishes to acknowledge the invaluable contribution made by dozens of SOFT and TIAFT members who assisted our distinguished International Advisory Board Members with the peerpeer----reviewreview of submitted abstracts. Inte rnational Advisory Board Members International Advisory Board Members Dan T Anderson, MS - USA Hans H Maurer, PhD - Germany Robert A Anderson, PhD - UK Manfred R Möller, PhD - Germany Sotiris Athanaselis, PhD - Greece Christine Moore, PhD - USA Elisabetta Bertol, PhD - Italy Ashraf Mozayani, PhD - USA Jochen Beyer, PhD - Australia Ilkka Ojanperä, PhD - Finland Federica Bortolotti, MD, PhD - Italy David Osselton, PhD - UK Jennifer Button, BS - UK Frank T Peters, PhD - Germany Hee-Sun Chung, PhD - Korea Simona Pichini, PhD - Italy Marc Deveaux, PhD - France Anya Pierce, MBA - Ireland Olaf H Drummer, PhD - Australia Nikolaos Raikos, MD - Greece Simon Elliott, PhD - UK Marina Stajic, PhD - USA Bradford R Hepler, PhD - USA Osamu Suzuki, MD, PhD - Japan David W Holt, PhD - UK Franco Tagliaro, MD - Italy Alan Wayne Jones, PhD - Sweden Helena Teixeira, PhD - Portugal Sarah Kerrigan, PhD - USA Alain G. Verstraete, MD - Belgium Pascal Kintz, PhD - France Robert Wennig, PhD - Luxembourg Thomas Kraemer, PhD - Switzerland Sarah Wille, PhD - Belgium Robert Kronstrand, PhD - Sweden Marc LeBeau, PhD - USA 2011 SOFT-TIAFT SCHEDULE OF EVENTS SUNDAY, 25 SEPTEMBER 2011 TIME ACTIVITY LOCATION 0700-1800 Registration Desk North Registration 0700-1800 Internet Café Yerba Buena Grand Assembly 0900-1130 TIAFT Board Meeting Salon 10-12 0900-1300 NCD-COAD General Meeting Walnut 1000-1300 Forensic Toxicology Council Meeting Pacific E 1130-1230 TIAFT Regional Representatives Meeting Salon 10-12 1230-1400 Young SOFT-TIAFT Lunch Off Site – Buca di Beppo 1400-1830 Young SOFT-TIAFT Symposium Salon 1,2,3,4 1400-1800 NLCP Inspector/Director Training Golden Gate A 1900-2100 Young SOFT-TIAFT Happy Hour Off Site - TBA MONDAY, 26 SEPTEMBER 2011 TIME ACTIVITY LOCATION 0600-0000 Hospitality Room Juniper 0700-1800 Registration Desk North Registration 0700-0800 Continental Breakfast Golden Gate Foyer 0730-0800 Sign In for Workshops 1, 2 and 3 Golden Gate Registration 0700-1800 Internet Café Yerba Buena Grand Assembly 0800-1200 Workshop 1 Golden Gate A 0800-1200 Workshop 2 Golden Gate B 0800-1200 Workshop 3 Golden Gate C 0900-1200 FTCB Examinations Sierra A 0900-1700 Exhibit Hall Set Up Yerba Buena 1000-1030 Break Golden Gate Foyer 1200-1330 Lunch for Workshop Attendees Jessie Square (Between Hotel and Jewish Contemporary Museum) 1300-1330 Sign In for Workshops 4, 5 and 6 Golden Gate Registration 1330-1730 Workshop 4 Golden Gate A 1330-1730 Workshop 5 Golden Gate C 1330-1730 Workshop 6 Golden Gate B 1330-1630 FTCB Board Meeting Pacific H 1500-1530 Break Golden Gate Foyer 1730-1830 SOFT/AAFS Drugs & Driving Committee Meeting Nob Hill C 1900-2200 Tier I Sponsors’ Receptions Agilent Technologies Club Room Thermo Scientific Foothill G TUESDAY, 27 SEPTEMBER 2011 TIME ACTIVITY LOCATION 0600-0000 Hospitality Room Juniper 0700-1800 Registration Desk North Registration 0700-0800 Continental Breakfast Golden Gate Foyer 0700-1200 SOFT Board Meeting Pacific H 0700-1800 Internet Café Yerba Buena Grand Assembly 0730-0800 Sign In for Workshops 7, 8 and 9 Golden Gate Registration 0800-1200 Workshop 7 Golden Gate B 0800-1200 Workshop 8 Golden Gate C 0800-1200 Workshop 9 Golden Gate A 0800-1200 ABFT Examinations Sierra A 0900-1200 ABFT Accreditation Committee Meeting Pacific C 0900-1700 Exhibit Hall Set Up Yerba Buena 1000-1030 Break Golden Gate Foyer 1200-1330 Lunch for Workshop Attendees Jessie Square (Between Hotel and Jewish Contemporary Museum) 1200-1800 ABFT Board Meeting Pacific C 1300-1330 Sign In for Workshops 10, 11 and 12 Golden Gate Registration 1330-1730 Workshop 10 Golden Gate B 1330-1730 Workshop 11 Golden Gate C 1330-1730 Workshop 12 Golden Gate A 1500-1530 Break Golden Gate Foyer 1730-1830 DFSA Committee Meeting Nob Hill C 1800 Sunshine/Rieders Silent Auction Opens Yerba Buena 1800-1900 Happy Hour in Exhibit Hall Yerba Buena 1800-1900 ABFT Certificant Reception Sierra A 1900-2100 Welcoming Reception in Exhibit Hall Yerba Buena 2100-2230 Elmer Gordon Forum Golden Gate A and B Historical Lecture by Professor Robert Wennig SWGTOX by Dr. Bruce Goldberger 2230-0030 Nite Owl by Cerilliant The View on the 39th Floor WEDNESDAY, 28 SEPTEMBER 2011 TIME ACTIVITY LOCATION 0600-0000 Hospitality Room Juniper 0700-1530 Registration Desk North Registration 0730-0830 Continental Breakfast Golden Gate Foyer 0700-1530 Internet Café Yerba Buena Grand Assembly 0830-1530 Exhibit Hall Open Yerba Buena 0830-0940 Opening Ceremony & Plenary Session Golden Gate A and B 1010-1155 Scientific Session 1 Golden Gate A 1010-1155 Scientific Session 2 Golden Gate B 1155-1340 Lunch & Poster Session 1 in Exhibit Hall Yerba Buena 1340-1440 Scientific Session 3 Golden Gate A 1340-1440 Scientific Session
Load more

Recommended publications
  • NINDS Custom Collection II
    ACACETIN ACEBUTOLOL HYDROCHLORIDE ACECLIDINE HYDROCHLORIDE ACEMETACIN ACETAMINOPHEN ACETAMINOSALOL ACETANILIDE ACETARSOL ACETAZOLAMIDE ACETOHYDROXAMIC ACID ACETRIAZOIC ACID ACETYL TYROSINE ETHYL ESTER ACETYLCARNITINE ACETYLCHOLINE ACETYLCYSTEINE ACETYLGLUCOSAMINE ACETYLGLUTAMIC ACID ACETYL-L-LEUCINE ACETYLPHENYLALANINE ACETYLSEROTONIN ACETYLTRYPTOPHAN ACEXAMIC ACID ACIVICIN ACLACINOMYCIN A1 ACONITINE ACRIFLAVINIUM HYDROCHLORIDE ACRISORCIN ACTINONIN ACYCLOVIR ADENOSINE PHOSPHATE ADENOSINE ADRENALINE BITARTRATE AESCULIN AJMALINE AKLAVINE HYDROCHLORIDE ALANYL-dl-LEUCINE ALANYL-dl-PHENYLALANINE ALAPROCLATE ALBENDAZOLE ALBUTEROL ALEXIDINE HYDROCHLORIDE ALLANTOIN ALLOPURINOL ALMOTRIPTAN ALOIN ALPRENOLOL ALTRETAMINE ALVERINE CITRATE AMANTADINE HYDROCHLORIDE AMBROXOL HYDROCHLORIDE AMCINONIDE AMIKACIN SULFATE AMILORIDE HYDROCHLORIDE 3-AMINOBENZAMIDE gamma-AMINOBUTYRIC ACID AMINOCAPROIC ACID N- (2-AMINOETHYL)-4-CHLOROBENZAMIDE (RO-16-6491) AMINOGLUTETHIMIDE AMINOHIPPURIC ACID AMINOHYDROXYBUTYRIC ACID AMINOLEVULINIC ACID HYDROCHLORIDE AMINOPHENAZONE 3-AMINOPROPANESULPHONIC ACID AMINOPYRIDINE 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE HYDROCHLORIDE AMINOTHIAZOLE AMIODARONE HYDROCHLORIDE AMIPRILOSE AMITRIPTYLINE HYDROCHLORIDE AMLODIPINE BESYLATE AMODIAQUINE DIHYDROCHLORIDE AMOXEPINE AMOXICILLIN AMPICILLIN SODIUM AMPROLIUM AMRINONE AMYGDALIN ANABASAMINE HYDROCHLORIDE ANABASINE HYDROCHLORIDE ANCITABINE HYDROCHLORIDE ANDROSTERONE SODIUM SULFATE ANIRACETAM ANISINDIONE ANISODAMINE ANISOMYCIN ANTAZOLINE PHOSPHATE ANTHRALIN ANTIMYCIN A (A1 shown) ANTIPYRINE APHYLLIC
    [Show full text]
  • GPCR/G Protein
    Inhibitors, Agonists, Screening Libraries www.MedChemExpress.com GPCR/G Protein G Protein Coupled Receptors (GPCRs) perceive many extracellular signals and transduce them to heterotrimeric G proteins, which further transduce these signals intracellular to appropriate downstream effectors and thereby play an important role in various signaling pathways. G proteins are specialized proteins with the ability to bind the nucleotides guanosine triphosphate (GTP) and guanosine diphosphate (GDP). In unstimulated cells, the state of G alpha is defined by its interaction with GDP, G beta-gamma, and a GPCR. Upon receptor stimulation by a ligand, G alpha dissociates from the receptor and G beta-gamma, and GTP is exchanged for the bound GDP, which leads to G alpha activation. G alpha then goes on to activate other molecules in the cell. These effects include activating the MAPK and PI3K pathways, as well as inhibition of the Na+/H+ exchanger in the plasma membrane, and the lowering of intracellular Ca2+ levels. Most human GPCRs can be grouped into five main families named; Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin, forming the GRAFS classification system. A series of studies showed that aberrant GPCR Signaling including those for GPCR-PCa, PSGR2, CaSR, GPR30, and GPR39 are associated with tumorigenesis or metastasis, thus interfering with these receptors and their downstream targets might provide an opportunity for the development of new strategies for cancer diagnosis, prevention and treatment. At present, modulators of GPCRs form a key area for the pharmaceutical industry, representing approximately 27% of all FDA-approved drugs. References: [1] Moreira IS. Biochim Biophys Acta. 2014 Jan;1840(1):16-33.
    [Show full text]
  • Rapid Screening for 61 Central Nervous System Drugs in Plasma
    African Journal of Pharmacy and Pharmacology Vol. 5(6), pp. 706-720, June 2011 Available online http://www.academicjournals.org/ajpp DOI: 10.5897/AJPP10.292 ISSN 1996-0816 ©2011 Academic Journals Full Length Research Paper Rapid screening for 61 central nervous system drugs in plasma using weak cation exchange solid-phase extraction and high performance liquid chromatography with diode array detection Yin Zhang1*, Wei-Ping Xie2, Chong-Hong Chen3 and Ling Lin4 1Department of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, People’s Republic of China. 2Department of Physical and Chemical Analysis, Quanzhou Center for Disease Control and Prevention, Quanzhou 362000, People’s Republic of China. 3Department of Pharmacology, College of Pharmacy, Fujian Medical University, Fuzhou 350004, People’s Republic of China. 4Department of Immunology, the Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, People’s Republic of China. Accepted 8 March, 2011 Rapid and accurate screening for toxicants/chemicals in a broad range is an important element in systematic toxicological analysis (STA). Herein, we report a novel method for the rapid screening of 61 central nervous system (CNS) drugs in plasma, using a solid-phase extraction (SPE) column termed, weak cation exchange (WCX) and high performance liquid chromatography with a diode array detector (HPLC-DAD). The SPE column was preconditioned sequentially with 3 ml of acetonitrile, 1 ml of water and, 2 ml of buffer solution. The pretreated plasma was loaded onto the column, which was then washed with 2 ml of water, followed by 2 ml of acetonitrile, and the acetonitrile elution was collected as the neutral/acid fraction.
    [Show full text]
  • Spectrum-Effect Relationships Between High
    Jiang et al Tropical Journal of Pharmaceutical Research February 2017; 16 (2): 379-386 ISSN: 1596-5996 (print); 1596-9827 (electronic) © Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria. All rights reserved. Available online at http://www.tjpr.org http://dx.doi.org/10.4314/tjpr.v16i2.17 Original Research Article Spectrum-effect relationships between high performance liquid chromatography fingerprint and analgesic property of Anisodus tanguticus (Maxim) Pascher (Solanaceae) roots Yun-Bin Jiang1, Mei Zhong2, Ming-Xun Hu1, Ling Chen1, Yan Gou3, Juan Zhou3, Pi-E Wu3 and Yu-Ying Ma1* 1College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, 2Analytical Chemistry Department, West China Frontier Pharmatech Co., Ltd/National Chengdu Center for Safety Evaluation of Drugs, Chengdu 610041, 3Laboratory for Traditional Chinese Medicine and Ethnic Medicine, Sichuan Institute for Food and Drug Control, Chengdu 610079, PR China *For correspondence: Email: [email protected] Received: 10 September 2016 Revised accepted: 11 January 2017 Abstract Purpose: To investigate the spectrum-effect relationships between high performance liquid chromatography with photodiode array detection (HPLC-DAD) fingerprint and analgesic activity of Anisodus tanguticus (Maxim.) Pascher (Solanaceae) (AT) roots. Methods: Analgesic activity of AT roots was evaluated by acetic acid-induced writhing test in mice. Fingerprint of AT roots was established by HPLC-DAD. After oral administration of AT roots extract, intra-gastric contents of caffeoylputrescine, anisodine, fabiatrin, scopolin, scopolamine, anisodamine and atropine in mice were determined by HPLC-DAD. Spectrum-effect relationships between HPLC- DAD fingerprint and analgesic activity were investigated using bivariate correlation analysis. Results: Following treatment with different batches of AT roots extract, acetic acid-induced writhing responses in mice were inhibited significantly (p < 0.05 or 0.01), with inhibitions of 26.62 - 55.13 %, relative to the control group.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] http://bmjopen.bmj.com/ on September 26, 2021 by guest. Protected copyright. BMJ Open BMJ Open: first published as 10.1136/bmjopen-2018-027935 on 5 May 2019. Downloaded from Treatment of stable chronic obstructive pulmonary disease: a protocol for a systematic review and evidence map Journal: BMJ Open ManuscriptFor ID peerbmjopen-2018-027935 review only Article Type: Protocol Date Submitted by the 15-Nov-2018 Author: Complete List of Authors: Dobler, Claudia; Mayo Clinic, Evidence-Based Practice Center, Robert D.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Anisodamine Item No. 19650 CAS Registry No.: 17659-49-3 Formal Name: αS-(hydroxymethyl)-benzeneacetic acid, 6-hydroxy-8-methyl-8- azabicyclo[3.2.1]oct-3-yl ester O Synonym: 6-hydroxy Hyoscyamine N HO MF: C17H23NO4 O FW: 305.4 Purity: ≥98% OH Supplied as: A crystalline solid Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Anisodamine is supplied as a crystalline solid. A stock solution may be made by dissolving the anisodamine in the solvent of choice. Anisodamine is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of anisodamine in ethanol and DMF is approximately 25 mg/ml, and approximately 20 mg/ml in DMSO. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of anisodamine can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of anisodamine in PBS, pH 7.2, is approximately 5 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description Anisodamine is a natural tropane alkaloid shown to be a weak antagonist of α1-adrenoceptors, blocking WB-4101 and clonidine (Item No. 15949) binding in brain membrane preparations with pKi values of 2.63 and 1.61, respectively.1 Anisodamine also has antioxidant effects that may protect against free radical-induced cellular damage.2 Anisodamine is predominantly found in the roots of A.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0269772 A1 Califano Et Al
    US 20090269772A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0269772 A1 Califano et al. (43) Pub. Date: Oct. 29, 2009 (54) SYSTEMS AND METHODS FOR Publication Classification IDENTIFYING COMBINATIONS OF (51) Int. Cl. COMPOUNDS OF THERAPEUTIC INTEREST CI2O I/68 (2006.01) CI2O 1/02 (2006.01) (76) Inventors: Andrea Califano, New York, NY G06N 5/02 (2006.01) (US); Riccardo Dalla-Favera, New (52) U.S. Cl. ........... 435/6: 435/29: 706/54; 707/E17.014 York, NY (US); Owen A. (57) ABSTRACT O'Connor, New York, NY (US) Systems, methods, and apparatus for searching for a combi nation of compounds of therapeutic interest are provided. Correspondence Address: Cell-based assays are performed, each cell-based assay JONES DAY exposing a different sample of cells to a different compound 222 EAST 41ST ST in a plurality of compounds. From the cell-based assays, a NEW YORK, NY 10017 (US) Subset of the tested compounds is selected. For each respec tive compound in the Subset, a molecular abundance profile from cells exposed to the respective compound is measured. (21) Appl. No.: 12/432,579 Targets of transcription factors and post-translational modu lators of transcription factor activity are inferred from the (22) Filed: Apr. 29, 2009 molecular abundance profile data using information theoretic measures. This data is used to construct an interaction net Related U.S. Application Data work. Variances in edges in the interaction network are used to determine the drug activity profile of compounds in the (60) Provisional application No. 61/048.875, filed on Apr.
    [Show full text]
  • Toxicology Reference Laboratory
    TOXICOLOGY REFERENCE LABORATORY Laboratory User Guide ROOM 708, BLOCK P PRINCESS MARGARET HOSPITAL 2-10 Princess Margaret Hospital Road Lai Chi Kok Tel: 2990 1941 Fax: 2990 1942 http://trl.home Version 6.1 Effective date: 1/July/2014 Contents Contents ..................................................................................................................................................... 2 Introduction ............................................................................................................................................... 4 Staff ............................................................................................................................................................ 5 Honorary Medical Staff .......................................................................................................................... 5 Scientific Staff ........................................................................................................................................ 5 Technical Staff ........................................................................................................................................ 5 Supportive Staff ...................................................................................................................................... 6 How to Make Laboratory Request .......................................................................................................... 7 Instruction for Referring Clinician ........................................................................................................
    [Show full text]
  • ( 12 ) United States Patent
    US010493080B2 (12 ) United States Patent (10 ) Patent No.: US 10,493,080 B2 Schultz et al. (45 ) Date of Patent : Dec. 3 , 2019 ( 54 ) DIRECTED DIFFERENTIATION OF (56 ) References Cited OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE U.S. PATENT DOCUMENTS 7,301,071 B2 11/2007 Zheng (71 ) Applicants : The Scripps Research Institute , La 7,304,071 B2 12/2007 Cochran et al. Jolla , CA (US ) ; Novartis AG , Basel 9,592,288 B2 3/2017 Schultz et al. 2003/0225072 A1 12/2003 Welsh et al. ( CH ) 2006/0258735 Al 11/2006 Meng et al. 2009/0155207 Al 6/2009 Hariri et al . (72 ) Inventors : Peter Schultz , La Jolla , CA (US ) ; Luke 2010/0189698 A1 7/2010 Willis Lairson , San Diego , CA (US ) ; Vishal 2012/0264719 Al 10/2012 Boulton Deshmukh , La Jolla , CA (US ) ; Costas 2016/0166687 Al 6/2016 Schultz et al. Lyssiotis , Boston , MA (US ) FOREIGN PATENT DOCUMENTS (73 ) Assignees : The Scripps Research Institute , La JP 10-218867 8/1998 Jolla , CA (US ) ; Novartis AG , Basel JP 2008-518896 5/2008 (CH ) JP 2010-533656 A 10/2010 WO 2008/143913 A1 11/2008 WO 2009/068668 Al 6/2009 ( * ) Notice : Subject to any disclaimer , the term of this WO 2009/153291 A1 12/2009 patent is extended or adjusted under 35 WO 2010/075239 Al 7/2010 U.S.C. 154 ( b ) by 0 days . (21 ) Appl. No .: 15 /418,572 OTHER PUBLICATIONS Molin - Holgado et al . “ Regulation of muscarinic receptor function in ( 22 ) Filed : Jan. 27 , 2017 developing oligodendrocytes by agonist exposure ” British Journal of Pharmacology, 2003 , 138 , pp .
    [Show full text]
  • Beneficial Effects of Anisodamine in Shock Involved Cholinergic Anti-Inflammatory Pathway
    MINI REVIEW ARTICLE published: 02 May 2011 doi: 10.3389/fphar.2011.00023 Beneficial effects of anisodamine in shock involved cholinergic anti-inflammatory pathway Ting Zhao, Dong-Jie Li, Chong Liu, Ding-Feng Su and Fu-Ming Shen* Department of Pharmacology, School of Pharmacy, Second Military Medical University, Shanghai, China Edited by: Anisodamine, an antagonist of muscarinic receptor, has been used therapeutically to improve Xue-Jun Sun, Taishan Medical College, blood flow in circulatory disorders such as septic shock in China since 1965. The main mechanism China of anisodamine for anti-shock proposed in Pharmacology for Chinese medical students is Reviewed by: Kayo Masuko, Sagami Women’s to improve blood flow in the microcirculation. Here, we suggest a new mechanism for its University, Japan anti-shock effect. That is, anisodamine, by blocking muscarinic receptor, results in rerouting Keliang Xie, General Hospital of Tianjin of acetylcholine to α7 nicotinic acetylcholine receptor (α7nAChR) bringing about increased Medical University, China acetylcholine-mediated activation of α7nAChR and the cholinergic anti-inflammatory pathway. *Correspondence: Fu-Ming Shen, Department of Keywords: anisodamine, acetylcholine, α7nAChR, inflammation, shock Pharmacology, School of Pharmacy, Second Military Medical University, 101 Guo He Road, Shanghai 200433, China. e-mail: [email protected] Anisodamine, a belladonna alkaloid isolated from the Chinese vascular leakage, stabilization of lysosomes and cathepsin inhib ition medicinal herb Scopolia tangutica Maxim (Figure 1) of the (Poupko et al., 2007). These actions of anisodamine resulted in the Solanaceae family indigenous to Tibet and first synthesized by ultimate improvement of blood flow in the microcirculation, which Chinese scientists in 1975, is an ester formed by the combination is the main mechanism proposed in the textbook of Pharmacology.
    [Show full text]
  • Novel Modulation of Adenylyl Cyclase Type 2 Jason Michael Conley Purdue University
    Purdue University Purdue e-Pubs Open Access Dissertations Theses and Dissertations Fall 2013 Novel Modulation of Adenylyl Cyclase Type 2 Jason Michael Conley Purdue University Follow this and additional works at: https://docs.lib.purdue.edu/open_access_dissertations Part of the Medicinal-Pharmaceutical Chemistry Commons Recommended Citation Conley, Jason Michael, "Novel Modulation of Adenylyl Cyclase Type 2" (2013). Open Access Dissertations. 211. https://docs.lib.purdue.edu/open_access_dissertations/211 This document has been made available through Purdue e-Pubs, a service of the Purdue University Libraries. Please contact [email protected] for additional information. Graduate School ETD Form 9 (Revised 12/07) PURDUE UNIVERSITY GRADUATE SCHOOL Thesis/Dissertation Acceptance This is to certify that the thesis/dissertation prepared By Jason Michael Conley Entitled NOVEL MODULATION OF ADENYLYL CYCLASE TYPE 2 Doctor of Philosophy For the degree of Is approved by the final examining committee: Val Watts Chair Gregory Hockerman Ryan Drenan Donald Ready To the best of my knowledge and as understood by the student in the Research Integrity and Copyright Disclaimer (Graduate School Form 20), this thesis/dissertation adheres to the provisions of Purdue University’s “Policy on Integrity in Research” and the use of copyrighted material. Approved by Major Professor(s): ____________________________________Val Watts ____________________________________ Approved by: Jean-Christophe Rochet 08/16/2013 Head of the Graduate Program Date i NOVEL MODULATION OF ADENYLYL CYCLASE TYPE 2 A Dissertation Submitted to the Faculty of Purdue University by Jason Michael Conley In Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy December 2013 Purdue University West Lafayette, Indiana ii For my parents iii ACKNOWLEDGEMENTS I am very grateful for the mentorship of Dr.
    [Show full text]
  • Alaska Care Is Currently My Secondary Coverage for Prescriptions (Primary Is Federal Employees Retirees Coverage, FEP 105 Through Blue Cross) )
    Alaska Care is currently my secondary coverage for prescriptions (primary is federal employees retirees coverage, FEP 105 through Blue Cross) ). Blue Cross just advised me that the coordination of benefits will change, and the EGWP will then become my primary prescription coverage, Do you agree with their assessment? The change, if it occurs, is fine with me as long as a national pharmacy chain, like Walgreens, will accept the change (they do accept the current AlaskaCare coverage) . Do you anticipate that the new Medicare part D plan will be widely accepted in Seattle? John Morrell 1 I'm a Medicaid elegable retiree under the DB plan. I get one of my prescriptions from the Aetna Specialty Pharmacy. How will the change to the Enhanced EGWP effect my access to this medication? Richard I'll. Sent from Yahoo Mail on Android 2 1) Oh My Goodness - look at the reviews of the new PBM by respected websites: https://www.consumeraffairs.com/rx/prescription_solutions.html https://www.law.com/ctlawtribune/2018/03/14/class-action-moves-forward-against-cigna-for-alleged-prescription- drug-overcharging/?slreturn=20180723142658 https://community.aarp.org/t5/Medicare-Insurance/DO-NOT-USE-OPTUMRx-to-fill-or-refill-you-prescriptions/td- p/85244 https://www.yelp.com/biz/optum-rx-sugar-land \ http://www.pharmaciststeve.com/?p=24318 among the many. Nothing above a one star rating. Could not have selected a worse provider 2) I am maxed out of Medicare surcharges - I cannot understand how the State of Alaska is going to save money on my account. My understanding from the Townhall meeting is the State will reimburse me $75 / month for these surchanges.
    [Show full text]